0
Diffuse Lung Disease: Treatment of IPF |

Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of Composite Physiologic Index at Baseline in the INPULSIS Trials

Athol Wells, MD; Juergen Behr, MD; Wibke Stansen, PhD; Susanne Stowasser, MD; Toby Maher, MD
Author and Funding Information

National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, United Kingdom


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):539A. doi:10.1016/j.chest.2016.08.553
Text Size: A A A
Published online

Extract

SESSION TITLE: Treatment of IPF

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Monday, October 24, 2016 at 07:30 AM - 08:30 AM

PURPOSE: In a pooled analysis of data from the two replicate Phase III INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF), nintedanib significantly reduced the risk of disease progression over 52 weeks, defined as an absolute decline in forced vital capacity (FVC) of ≥5% predicted or death, or ≥10% predicted or death, versus placebo. We investigated whether nintedanib had the same effect on disease progression in subgroups defined by composite physiologic index (CPI) at baseline, a measure that reflects the extent of pulmonary fibrosis on computed tomography (i.e. a higher score is worse) and is associated with prognosis.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543